Lai Jimmy S M, Chua John K H, Tham Clement C Y, Lam Dennis S C
Department of Ophthalmology, United Christian Hospital, Kwun Tong, Kowloon, Hong Kong, China.
Clin Exp Ophthalmol. 2004 Aug;32(4):368-72. doi: 10.1111/j.1442-9071.2004.00839.x.
To study the effectiveness and safety of selective laser trabeculoplasty (SLT) on primary open-angle glaucoma and ocular hypertension in Chinese eyes.
This was a prospective randomized controlled clinical study in which 58 eyes of 29 patients with primary open-angle glaucoma or ocular hypertension were included. One eye of each patient was randomized to receive SLT (Group 1) and the fellow eyes received medical treatment (Group 2). Patients were evaluated after laser treatment at 2 h, 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, and then yearly.
All patients (13 male, 16 female) were Chinese. The mean age was 51.9 +/- 14.7 years. The mean baseline intraocular pressure was 26.8 +/- 5.6 mmHg in group 1 and 26.2 +/- 4.2 mmHg in group 2 (P = 0.62). The failure rate, defined as intraocular pressure >21 mmHg with maximal medications, was 17.2% in group 1 and 27.6% in group 2 at 5-year follow-up (P = 0.53). Eight eyes (27.6%) in group 1 required medications to control the intraocular pressure to below 21 mmHg. There was no statistically significant difference in the intraocular pressure reductions between the two groups at all time intervals (P > 0.05). The mean number of antiglaucoma medications was significantly lower in the SLT than the medical treatment group up to 5 years of follow up (P < 0.001). Transient post-SLT intraocular pressure spike >5 mmHg was observed in three eyes (10.3%).
With fewer medications, SLT gives similar intraocular pressure reduction to medical therapy alone in Chinese patients with primary open-angle glaucoma or ocular hypertension.
研究选择性激光小梁成形术(SLT)对中国患者原发性开角型青光眼和高眼压症的有效性和安全性。
这是一项前瞻性随机对照临床研究,纳入了29例原发性开角型青光眼或高眼压症患者的58只眼。每位患者的一只眼睛随机接受SLT治疗(第1组),另一只眼睛接受药物治疗(第2组)。在激光治疗后2小时、1天、1周、2周、1个月、3个月、6个月进行评估,之后每年评估一次。
所有患者(13例男性,16例女性)均为中国人。平均年龄为51.9±14.7岁。第1组平均基线眼压为26.8±5.6 mmHg,第2组为26.2±4.2 mmHg(P = 0.62)。在5年随访时,定义为使用最大剂量药物后眼压>21 mmHg的失败率,第1组为17.2%,第2组为27.6%(P = 0.53)。第1组有8只眼(27.6%)需要药物治疗以将眼压控制在21 mmHg以下。在所有时间间隔内,两组眼压降低情况无统计学显著差异(P>0.05)。在长达5年的随访中,SLT组抗青光眼药物的平均使用数量显著低于药物治疗组(P<0.001)。3只眼(10.3%)观察到SLT术后短暂眼压峰值>5 mmHg。
对于中国原发性开角型青光眼或高眼压症患者,SLT与单纯药物治疗降低眼压效果相似,但用药更少。